The threat of bacterial biofilms
Bacteria naturally prefer biofilm environments
- Slime-like, protected communities of bacteria that shield bacteria from immune or antibiotic attack
- Composed of extracellular polymeric substance (EPS) and a scaffolding matrix of extracellular DNA (eDNA) and “linchpin” (red) binding proteins
Biofilms protect bacteria
and drive resistance
Drive antibiotic failure, antibiotic resistance, inflammatory responses, and poor clinical outcomes
- Responsible for approximately 80 percent of human bacterial infections
- Biofilm-encased bacteria can be up to 1,000 times more resistant to antibiotics than those unprotected by biofilms
The Clarametyx Technology
Powerful Non-Antibiotic and pathogen-agnostic biologic technology
CMTX-101 (purple) antibodies capture and remove key linchpin proteins (red), resulting in rapid biofilm collapse
Key modes of action:
- Immune-enabling: Enables a more efficient immune reaction to eliminate disease-causing bacteria
- Antibiotic-sensitizing: Enhances the effectiveness of antibiotic activity
- Inflammation-suppressing: Decreases biofilm-associated inflammation and reduces inflammatory reaction without impairing immune response
Biofilm collapse
drastically increases
bacterial vulnerability
- Antibiotic susceptibility increased by 4 to 8 fold
- Antibiotics and innate immune effectors able to access bacteria
Unprotected bacteria
are rapidly destroyed
- First line antibiotics and innate immune response more effective
- Multi-faceted pro-stewardship benefits, reduced potential for development of antibiotic resistance
- High potential for cost-effective clinical benefit
